[Special Stock] Trump Treatment Remdesivir-Related Stocks Rise... Pharmicell Up 16%
[Asia Economy Reporter Minji Lee] As it has been reported that U.S. President Donald Trump received the antiviral drug Remdesivir for the treatment of the novel coronavirus infection (COVID-19), related stocks are showing an upward trend in the domestic stock market.
At 9:08 a.m. on the 5th in the KOSPI market, Pharmicell was traded at 20,950 KRW, up 16% from the previous session. In addition, Jinwon Life Sciences (5.23%), HanAll Biopharma (2.8%), Shinpung Pharmaceutical (1.6%), Aprogen Pharmaceuticals (1.5%), and Access Bio (1.3%) are maintaining an upward trend.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
While U.S. President Trump is hospitalized due to COVID-19, his medical team held a press conference on the 4th (local time) stating, "The second dose of Remdesivir has been completed," and explained, "We have been monitoring for possible side effects and have not experienced any notable side effects."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
